Morphotek Announces 3 Presentations on Its Lead Therapeutic Candidates MORAb-003 and MORAb-009 at the 2006 American Society of Clinical Oncology Meeting
17th May 2006, 15:49 GMT
Morphotek a biopharmaceutical company, has 2 presentations on its lead monoclonal antibody product candidate, MORAb-003, as well as an oral presentation on its monoclonal antibody MORAb-009 at the 42nd annual meeting of the American Society of Clinical Oncology being held in Atlanta, GA.
Morphotek Announces 3 Presentations on Its Lead Therapeutic Candidates MORAb-003 and MORAb-009 at the 2006 American Society of Clinical Oncology Meeting related news:
- New Phase III Data on Renin Inhibitor SPP100 in Treatment of Hypertension Demonstrates Potential of This 1st-in-Class Drug — StratWire - Business of Healthcare NewsFeed
- Oncology Journalism Award - 2006 Luminous Award Australia — Medical News Today RSS/XML Feed
- Medicure Presents Matched Results at the 21st Annual Meeting of the American Society of Hypertension — ArriveNet : Health
- Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at the American Society of Hypertension Annual Meeting — ArriveNet : Press Releases
- Repeat - Novartis Announces Efficacy Data on New Investigational High Blood Pressure Therapies at the American Society of Hypertension Annual Meeting — ArriveNet : Health
- TOPIGEN: TOPIGEN Announces Preclinical Data and Acceptance to Present at the American Thoracic Society Conference — Market Wire - Financial Services
- American Geriatrics Society 2006 Annual Scientific Meeting — Medscape Headlines
- Aeolus Pharmaceuticals Announces Q2 Financial Results — Radiology News from StratCenter.com
- American Society of Hypertension 21st Annual Scientific Meeting and Exposition — Medscape Headlines
- Sepracor to Present Arformoterol Phase III Data at American Thoracic Society Annual Conference — Pulmonary/ Respiratory News from StratCenter.com
Latest news from Obstetrics/ Gynecology News from StratCenter.com:
- Acusphere Reports Q3 2006 Financial Results and Accomplishments
- CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
- Twin Cities Takes Action to Save Babies
- Substantial Regression of Atherosclerosis May Help Improve Diseased Arteries
- EDAP TMS SA to Participate in Int'l Urology Conferences
- Misonix Showcases SonicOne Ultrasonic Wound Debrider with Medline at MEDICA 2006 in Germany
- 8 Studies Evaluating Cytyc's Novasure System Presented at AAGL Meeting